organization

TPIZ

TAKEDA PHARMACEUTICALS INTERNATIONAL AG
19 projects, page 1 of 4
  • project . 2020 - 2021
    Funder: EC Project Code: 101005177
    Overall Budget: 10,329,300 EURFunder Contribution: 9,592,030 EUR
    Open Access mandate for Publications
    Partners: AVA AG, UCL, ROCHE DIAGNOSTICS NEDERLAND BV, JCR, Stichting Sanquin Bloedvoorziening, UMC, TPIZ, Labormedizinische Zentrum Dr Risch (Switzerland), VIVE - Det Nationale Forsknings- og Analysecenter For Velfærd

    In this project, we will evaluate the use and performance of a CE-marked device (wearable), which uses sensors to measure breathing rate, pulse rate, skin temperature, and heart rate variability for the purpose of early detection and monitoring of COVID-19 in general an...

  • project . 2019 - 2022
    Funder: EC Project Code: 821513
    Overall Budget: 2,353,120 EURFunder Contribution: 1,199,120 EUR
    Open Access mandate for Publications and Research Data
    Partners: AE, Eli Lilly and Company Limited, JANSSEN PHARMACEUTICA NV, SARD, NICE, SYNAPSE, Roche (Switzerland), PARKINSON'S UK, TPIZ, TAKEDA DEVELOPMENT CENTRE EUROPE LTD

    The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dov...

  • project . 2019 - 2022
    Funder: EC Project Code: 806999
    Overall Budget: 7,644,400 EURFunder Contribution: 4,999,760 EUR
    Open Access mandate for Publications
    Partners: SOFTWARE AG, THE HYVE, King's College London, JANSSEN PHARMACEUTICA NV, AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN, UOXF, AE, FOUNDATION LYGATURE, Karolinska Institutet Innovations (Sweden), CENTRE FOR RESEARCH AND TECHNOLOGY HELLAS CERTH...

    There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful c...

  • project . 2018 - 2021
    Funder: EC Project Code: 807012
    Overall Budget: 3,100,690 EURFunder Contribution: 1,750,000 EUR
    Open Access mandate for Publications and Research Data
    Partners: IAPO, Eli Lilly and Company Limited, Zorginstituut Nederland, Bayer AG, TPIZ, ASTRAZENECA AB, VT, NICE, YAMANOUCHI EUROPE BROCADES PHARMA, UNIVERSITAIR MEDISCH CENTRUM GRONINGEN...

    The GetReal Initiative brings together partners from the IMI GetReal project to drive the adoption of tools, methodologies and best practices from IMI GetReal and increase the quality of real-world evidence (RWE) generation in medicines development and regulatory/HTA pr...

  • project . 2019 - 2022
    Funder: EC Project Code: 821362
    Overall Budget: 8,872,550 EURFunder Contribution: 4,599,650 EUR
    Open Access mandate for Publications
    Partners: ARTTIC INNOVATION GMBH, ARTTIC, PFIZER, BIONEER A/S, Bayer AG, KUL, JANSSEN PHARMACEUTICA NV, INSTITUT DE RECHERCHES SERVIER, FCDI, Novo Nordisk...

    EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells...

19 projects, page 1 of 4
Any information missing or wrong?Report an Issue